

AD \_\_\_\_\_

GRANT NO: DAMD17-94-J-4154

**TITLE:**


Genetic Construction and Molecular Characterization of  
Breast Cancer Precursor Cells

**PRINCIPAL INVESTIGATOR:**

Kimberly M. Spancake

**CONTRACTING ORGANIZATION:**

University of Utah, Graduate School  
Salt Lake City, Utah 84112



**REPORT DATE:**

June 30, 1995

**TYPE OF REPORT:**

Annual

PREPARED FOR: U.S. Army Medical Research and Materiel  
Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

19950828 073

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 5

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE June 30, 1995		3. REPORT TYPE AND DATES COVERED Annual 31 May 94 - 30 May 95	
4. TITLE AND SUBTITLE  Genetic Construction and Molecular Characterization of Breast Cancer Precursor Cells				5. FUNDING NUMBERS  DAMD17-94-J-4154	
6. AUTHOR(S)  Kimberly M. Spancake					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  University of Utah, Graduate School  Salt Lake City, Utah 84112				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES					
12a. DISTRIBUTION/AVAILABILITY STATEMENT  Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words)  Mutations in genes involved in cell-cycle and growth regulation, such as the retinoblastoma gene (RB), are expected to have a significant role in the early stages of breast cancer. RB-deficient cells are being created by two distinct methods. First, targeting vectors, currently being constructed, will be transfected into human mammary epithelial cell lines (HMEC) in order to knock out both RB alleles via homologous recombination. Second, a human papilloma virus (HPV) E6/E7 fusion construct, previously shown to specifically target the retinoblastoma protein (pRb) for degradation, will be transfected into HMEC. The E6/E7 gene fusion will be introduced into the HMEC under the control of a regulatable promoter, allowing for direct regulation of protein expression. Breast cells made deficient for pRb by these two methods will be examined for cellular and molecular alterations, such as changes in morphology and behavior, and their ability to form duct-like structures when grown on or within an extracellular matrix. Additionally, since the normal RB product has been implicated in transcriptional regulation, the effect on mRNA transcription in the RB-deficient breast cells will be assayed by Northern blot analysis and differential display.					
14. SUBJECT TERMS Breast Cancer; Mammary Epithelial Cells; Retinoblastoma; Homologous Recombination; E6/E7 fusion; Differential Display				15. NUMBER OF PAGES 12	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited		

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

  X   Where copyrighted material is quoted, permission has been obtained to use such material.

  X   Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

  X   Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

  X   In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).


  X   For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

  X   In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

  X   In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

  X   In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Accession For	
HTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution _____	
Availability Codes	
Dist	Avail and/or Special
A-1	

 PI Signature June 28, 1995 Date

## TABLE OF CONTENTS

Page #(s):

1.	Front Cover
2.	SF298
3.	Foreward
4.	Table of Contents
5.	Introduction
6-7.	Body of Report
8.	Conclusions
9.	References
10-12.	Appendices: Figures 1,2; Table 1; Additional Information

## INTRODUCTION

### Genetic Construction and Molecular Characterization of Breast Cancer Precursor Cells

The retinoblastoma gene has been shown to be inactivated in 20% of human breast tumors and 25% of human breast carcinoma cell lines by conventional loss of heterozygosity (LOH) studies<sup>1,2</sup>. More recently, LOH of *RB* was demonstrated in the majority of breast carcinomas (59%) after tumor cell enrichment by cell sorting<sup>3</sup>. Researchers have also found an increase in the incidence of breast cancer in a family with a constitutional *RB* mutation<sup>4</sup>. The observations of *RB* LOH in breast tumors and the increase of breast cancer incidence in an *RB*-family suggest an important role for *RB* in breast carcinogenesis. Additional studies have shown that restoration of pRb expression in breast carcinoma cell lines with *RB* mutations causes a reduction in the cells' ability to grow in soft agar and form tumors in nude mice<sup>5</sup>. This data provides functional evidence for *RB* playing a role in breast carcinogenesis.

I am currently investigating the role of *RB* in breast carcinogenesis. Specifically, my hypothesis is that elimination of functional pRb from HMEC will promote cellular changes that mimic an early stage in the progression of breast carcinogenesis. Removing pRb will cause discernible cellular and molecular alterations resulting from changes in the transcription of pRb-related genes.

### SPECIFIC AIMS

#### Specific Aim 1. Construct HMEC deficient for pRb.

Breast epithelial cells are currently being made deficient for pRb by two independent methods. First, targeting vectors, specific for *RB*, will be transfected into HMEC and *RB* knockouts selected by drug resistance. Second, the viral transforming protein HPV E6/E7 gene fusion construct will be expressed in HMEC, functionally deleting *RB* by inactivating pRb.

#### Specific Aim 2. Characterize the RB-deficient cell lines

RB-deficient cells created in specific aim one will be characterized by several criteria. Cells will be assayed for changes in morphology, growth rate, transformation properties, and ability to form duct-like structures on an extracellular matrix. Since pRb plays an active role in transcription regulation, changes in mRNA transcription also will be examined.

## BODY OF REPORT

Specific aim number one has served as the focus of my most recent research, including the May 1994 to May 1995 time period.

### **Approach #1: Construct HMEC containing homozygous deletions of *RB***

As mentioned previously, I am constructing RB-deficient cells by two separate methods. HMEC *RB* knockouts will be created via homologous recombination using replacement vectors, currently under construction, to completely delete both *RB* alleles. The targeting vectors are pUC9 derivatives that contain three essential components: a positive selectable marker (neomycin or hygromycin), a negative selectable marker (Herpes simplex virus thymidine kinase gene, *HSV-tk*), and 6 kb each of DNA from both the 5' and 3' regions of *RB* (Figure 1).

An 81-nucleotide DNA oligomer and its complementary strand were synthesized on an ABI 394 DNA/RNA synthesizer. The 81-mers, when annealed, serve as a polylinker containing all the restriction endonuclease sites necessary for the subsequent cloning steps. The 81-mers were PCR amplified, digested with *EcoRI* and *Hind III*, and cloned into pUC9. The neomycin drug resistance gene was then cloned into the corresponding region of the polylinker. The 3' and 5' *RB* clones and the two *HSV-tk* genes are currently being cloned into this specialized pUC9 plasmid. These knockout vectors will be linearized with the restriction endonuclease *AatII* and transfected into HMEC by lipofection; cells will be screened for successful integration by culturing in media containing G418/hygromycin and gancyclovir.

### **Approach #2: Construct HMEC with conditionally-deficient pRb**

Interactions between the tumor suppressor proteins pRb and p53 and transforming proteins of various DNA tumor viruses are thought to be essential components of the transformation process. Two Human Papillomavirus (HPV) early genes, E6 and E7, bind p53 and pRb, respectively<sup>6,7</sup>. Binding of HPV type-16 (HPV-16) E6 to p53 enhances degradation of the p53 protein<sup>8</sup>. Binding of HPV-16 E7 to pRb inactivates pRb by mimicking the hyperphosphorylated state, disrupting pRb interactions with other proteins, and thus effectively deleting pRb without actually knocking out both *RB* alleles. A fusion protein consisting of the full-length HPV-11 E6 protein and the HPV-16 E7 pRb-binding domain induces the *in vitro* degradation of pRb without effecting p53 degradation<sup>9</sup>. Expression of this E6/E7 construct in HMEC should cause degradation of pRb, creating an RB-deficient cell line.

Since the metabolic consequences of this experiment are not known, using the E6/E7 construct in a conditional expression system will allow for better control of the experiment. Two different regulatable systems are being used. A sheep metallothionein promoter construct was recently obtained by our laboratory and will be used for inducible regulation of E6/E7 expression<sup>10</sup>. The E6/E7 fusion construct will be cloned into the MT-CB6+ plasmid, transfected into HMEC, and expression levels regulated by varying the concentration of ZnSO<sub>4</sub> in the growth media.

The second system to control E6/E7 expression is regulated by tetracycline-responsive promoters

and will be used to control E6/E7 expression<sup>11</sup>. Briefly, the plasmid pUHD15.1 contains a transactivator (tTA) which, when expressed, binds to a tetracycline operator and minimal promoter sequence on a second plasmid, pUHC13.3 (Figure 2). This binding of the tTA stimulates transcription of luciferase or a gene of interest and transcription can be regulated by culturing the cells with varying concentrations of tetracycline. HMEC will be made conditionally deficient for pRb by transfection of the HPV E6/E7 fusion construct under the control of tetracycline-inducible system. The tTA on the pUHD15.1 (neo<sup>R</sup>) plasmid will be transfected into early-passage 184 and 184A1 cells. Cells that have been successfully, stably transfected with pUHD15.1 will be selected by culturing in 200 µg/ml GENETICIN<sup>R</sup> (G418). Responsiveness to tetracycline will be tested by transient transfection with the pUHC13.3 luciferase<sup>+</sup> construct into the G418-resistant 184 and 184A1 cells. The pUHC13.3 (hygro<sup>R</sup>) vector will be modified by replacing the luciferase gene with the E6/E7 construct, placing E6/E7 under the control of the tetracycline promoter. This construct will be transfected into previously established G418-resistant 184(tTA) and 184A1(tTA) cells. Successful transfection of the E6/E7-modified pUHC13.3 vector will be selected by culturing in media containing hygromycin and subsequently tested for tetracycline-induced regulation of E6/E7. Levels of E6/E7 fusion protein and pRb will be determined using immunoprecipitation with the appropriate antibodies.

Preliminary experiments with the tetracycline-repressible system indicate that it is functional in the 184A1 cell line. pUHD15.1 and pUHC13.3 constructs were transiently expressed in the 184A1 cell line to assay the degree of regulation that could be obtained with this tetracycline system in these HMEC. 184A1 cells were grown in 60 mm dishes until they reached 80 - 85 % confluency at which time they were transfected using lipofection (DOTAP, Boehringer Mannheim). Nine different conditions were assayed: (1) no DNA or DOTAP, (2) DOTAP (1 & 2 served as negative controls), (3) a luciferase construct driven by an SV40 promoter (positive control), (4) pUHD15.1, (5) pUHC13.3, (6) pUHC13.3 plus 1.0 µg/ml tetracycline, (7) pUHD15.1 and pUHC13.3, (8) pUHD15.1 and pUHC13.3 plus 0.1 µg/ml tetracycline, and (9) pUHD15.1 and pUHC13.3 plus 1.0 µg/ml tetracycline. DNA and DOTAP were mixed, added to the cells, and incubated for 6 hours. The DNA/DOTAP containing media was then aspirated and replaced with fresh media (containing tetracycline, where indicated). Cells were grown an additional 48 hours before lysis. Lysates were assayed for luciferase activity using the Luciferase Assay System (Promega), and quantitated using a luminometer (Table 1). These results show that in 184A1 cells, tetracycline inhibits the luciferase expression driven by the transactivator by 20 - 30 fold (comparing luminometer readings from pUHD15.1 and pUHC13.3 versus both vectors in the presence of tetracycline). The results also indicate that this inducible system is functional in the 184A1 cell line and, as such, is encouraging for future stable transfection experiments.

## CONCLUSIONS

1. The *RB* targeting vector being constructed is half-way to completion and, upon completion, will be transfected into different HMEC. The RB-deficient cells will be identified by growth selection and further characterized by the criteria described in the original report.
2. Transient transfection of the tetracycline-repressible system indicates that these constructs are functional in the 184A1 cell line and expression can be regulated 20-30 fold. The E6/E7 fusion construct will be expressed in different HMEC using this system as well as the inducible, sheep metallothionein construct. RB-deficient cells created using these systems will also be characterized as described previously.



## REFERENCES

1. Fung Y.-K.T. and T'Ang A. (1992). The role of the retinoblastoma gene in breast cancer development. *Cancer Treat. Res.* **61**: 59-68.
2. T'Ang A., Varley J.M., Chakraborty S., Murphee A.L., and Fung Y.-K.T. (1988). Structural rearrangement of the retinoblastoma gene in human breast carcinoma. *Science*. **242**: 263-266.
3. Tamura, G., Maesawa, C., Suzuki, Y., Kashiwaba, M., Ishida, M., Saito, K., and Satodate, R. (1994). Improved detection of loss of heterozygosity at retinoblastoma gene locus in human breast carcinoma. *Pathol. Int.* **44**: 34-38.
4. Thorlacius, S., Jonasdottir, O., and Eyfjord, J.E. (1991). Loss of heterozygosity at selective sites on chromosomes 13 and 17 in human breast carcinoma. *Anticancer Res.* **11**: 1501-1508.
5. Wang, N.P., To, H., Lee, W.-H., and Lee, E.Y.-H.P. (1993). Tumor suppressor activity of *RB* and *p53* genes in human breast carcinoma cells. *Oncogene* **8**: 279-288.
6. Werness B.A., Levine A.J., and Howley P.M. (1990). Association of human papillomavirus types 16 and 18 E6 proteins with p53. *Science* **248**: 76-79.
7. Munger K., Phelps W.C., Bubb V., Howley P.M., and Schlegel R. (1989). The E6 and E7 genes of human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. *J. Virol.* **63**: 4417-4421.
8. Band V., Dalal S., Delmolino L., and Androphy E.J. (1993). Enhanced degradation of p53 protein in HPV-6 and HPV-11 E6-immortalized human mammary epithelial cells. *EMBO J.* **12**: 1847-1852.
9. Scheffner, M., Munger, K., Huibregtse, J.M., and Howley, P.M. (1992). Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion proteins. *EMBO J.* **11**: 2425-2431.
10. MT-CB6+ vector construct obtained from Dr. Frank Rausher.
11. Gossen M. and Bujard H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc. Natl. Acad. Sci. USA* **89**: 5547-5551.

## APPENDIX




Figure 1. Schematic representation of the *RB* targeting vector. The *RB* targeting vector contains a positive selectable marker (neomycin or hygromycin) flanked by the 5' and 3' most *RB* sequence. Additionally, the vector contains two negative selectable markers, HSV-*tk* genes. This construct will be used to knock out *RB* in HMEC.

	Expected Results	Experiment #1	Experiment #2
Control (No DNA or DOTAP)	-	0.128	0.175
DOTAP	-	0.123	0.191
SV40-luciferase	+++	ND	37.350
pUHD15.1	-	0.136	0.179
pUHC13.3	-	160.700	10.910
pUHC13.3 & 1.0 µg/ml tet.	-	ND	3.734
pUHD15.1 + pUHC13.3	+++	22.890	60.650
pUHD15.1 + pUHC13.3 & 0.1 µg/ml tet.	+(+)	0.755	3.230
pUHD15.1 + pUHC13.3 & 1.0 µg/ml tet.	-	0.815	2.025

all dishes, 20 µg total DNA (pUHD15.1 and pUHC13.3, 5:1)

+/- indicates relative levels of luciferase expression

ND not determined

tet. tetracycline

Table 1. Expression levels of luciferase using the tetracycline inducible system transiently transfected into 184A1 cells.

## APPENDIX




Figure 2. Tetracycline-regulated system<sup>11</sup>. A chimeric tetracycline-controlled transactivator (tTA) was constructed by fusing a bacterial tetracycline repressor with the herpes simplex virus VP16 activation domain. This transactivator stimulates transcription of a gene of interest, such as the E6/E7 fusion, from a construct containing tetracycline operator sequences and a minimal promoter sequence derived from human cytomegalovirus (CMV). Tetracycline, added to the cell culture media, blocks the transactivator thus decreasing the level of transcription from the gene of interest. This control system allows an individual gene to be regulated over up to five orders of magnitude in HeLa cells.

**APPENDIX**  
**ADDITIONAL INFORMATION**

July 19, 1994 -- Poster presentation. Construction and Molecular Characterization of Breast Cells  
Containing Early Genetic Alterations.

American Association for Cancer Research. Histopathobiology of Neoplasia Workshop.  
Keystone, Colorado.

March 1, 1995 -- Passed qualifying examination for the department of human genetics.